-+ 0.00%
-+ 0.00%
-+ 0.00%

SAVARA PRESENTED LONG-TERM EFFICACY AND SAFETY DATA FROM THE ONGOING IMPALA-2 PHASE 3 CLINICAL TRIAL OPEN-LABEL (OL) EXTENSION OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP)

Reuters·05/19/2026 18:15:00

Please log in to view news